Radical prostatectomy is a treatment option for clinically localised prostate cancer; however, approximately 20% of men will develop biochemical failure, defined as two or more consecutive prostate specific antigen (PSA) values of >0.20 ng/mL within 5 years of treatment [1, 2]. The gene discussed is KLK3; the disease is Familial prostate cancer.